Non-invasive in vivo assessment of 11β-hydroxysteroid dehydrogenase type 1 activity by 19F-Magnetic Resonance Spectroscopy

[1]  B. Sitter.  Urinary detection of corticosteroid in topical treatment of skin disease by 19F MRS , 2019, Magnetic Resonance Materials in Physics, Biology and Medicine.

[2]  B. Walker,et al.  Quantification of 11β-hydroxysteroid dehydrogenase 1 kinetics and pharmacodynamic effects of inhibitors in brain using mass spectrometry imaging and stable-isotope tracers in mice , 2018, Biochemical pharmacology.

[3]  Ravi S. Menon,et al.  Diffusion-weighted tractography in the common marmoset monkey at 9.4T. , 2017, Journal of neurophysiology.

[4]  B. Walker,et al.  Selection and early clinical evaluation of the brain‐penetrant 11β‐hydroxysteroid dehydrogenase type 1 (11β‐HSD1) inhibitor UE2343 (Xanamem™) , 2017, British journal of pharmacology.

[5]  Peter R Seevinck,et al.  19 F MRSI of capecitabine in the liver at 7 T using broadband transmit–receive antennas and dual‐band RF pulses , 2015, NMR in biomedicine.

[6]  B. Walker,et al.  Cognitive and Disease-Modifying Effects of 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibition in Male Tg2576 Mice, a Model of Alzheimer's Disease , 2015, Endocrinology.

[7]  T. Niendorf,et al.  Eight‐channel transceiver RF coil array tailored for 1H/19F MR of the human knee and fluorinated drugs at 7.0 T , 2015, NMR in biomedicine.

[8]  S. Van Huffel,et al.  Quantification of in vivo 1H magnetic resonance spectroscopy signals with baseline and lineshape estimation , 2011 .

[9]  D. Befroy,et al.  Magnetic Resonance Spectroscopy Studies of Human Metabolism , 2011, Diabetes.

[10]  J. Seckl,et al.  11β-Hydroxysteroid Dehydrogenase Type 1 Expression Is Increased in the Aged Mouse Hippocampus and Parietal Cortex and Causes Memory Impairments , 2010, The Journal of Neuroscience.

[11]  J. Rosenstock,et al.  The 11-β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy , 2010, Diabetes Care.

[12]  P. Dagnelie,et al.  Magnetic resonance spectroscopy to study hepatic metabolism in diffuse liver diseases, diabetes and cancer. , 2010, World journal of gastroenterology.

[13]  Jeffry R Alger,et al.  Quantitative Proton Magnetic Resonance Spectroscopy and Spectroscopic Imaging of the Brain: A Didactic Review , 2010, Topics in magnetic resonance imaging : TMRI.

[14]  Zenon Starčuk,et al.  Quantitation of magnetic resonance spectroscopy signals: the jMRUI software package , 2009 .

[15]  P. Stewart,et al.  Modulation of 11β-Hydroxysteroid Dehydrogenase (11βHSD) Activity Biomarkers and Pharmacokinetics of PF-00915275, a Selective 11βHSD1 Inhibitor , 2008 .

[16]  T. Scheenen,et al.  Quantitative 19F MR spectroscopy at 3 T to detect heterogeneous capecitabine metabolism in human liver , 2007, NMR in biomedicine.

[17]  J. McKew,et al.  β-Keto sulfones as inhibitors of 11β-hydroxysteroid dehydrogenase type I and the mechanism of action , 2007 .

[18]  B. Walker,et al.  Discovery and biological evaluation of adamantyl amide 11beta-HSD1 inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[19]  A Heerschap,et al.  Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium‐DTPA‐enhanced MRI and localized 19F MRS pharmacokinetic studies of 5‐fluorouracil , 2007, NMR in biomedicine.

[20]  R. Thieringer,et al.  11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice , 2005, The Journal of experimental medicine.

[21]  M. Malet‐Martino,et al.  Fluorine-19 or phosphorus-31 NMR spectroscopy: a suitable analytical technique for quantitative in vitro metabolic studies of fluorinated or phosphorylated drugs. , 2005, Journal of pharmaceutical and biomedical analysis.

[22]  Zoltan Balazs,et al.  Comparative enzymology of 11β-hydroxysteroid dehydrogenase type 1 from six species , 2005 .

[23]  B. Walker,et al.  The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans. , 2005, Diabetes.

[24]  B. Walker,et al.  Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. , 2005, Diabetes.

[25]  D. Collins,et al.  Quantitative assessment of the hepatic pharmacokinetics of the antimicrobial sitafloxacin in humans using in vivoF magnetic resonance spectroscopy. , 2005, British journal of clinical pharmacology.

[26]  B. Walker,et al.  11β-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory , 2004, Trends in Endocrinology & Metabolism.

[27]  J. Čejková,et al.  High-resolution magic angle spinning 1H NMR spectroscopy of metabolic changes in rabbit lens after treatment with dexamethasone combined with UVB exposure , 2004, Graefe's Archive for Clinical and Experimental Ophthalmology.

[28]  Arend Heerschap,et al.  19F-magnetic resonance spectroscopy in patients with liver metastases of colorectal cancer treated with 5-fluorouracil , 2004, Anti-cancer drugs.

[29]  Dennis W J Klomp,et al.  In vivo monitoring of capecitabine metabolism in human liver by 19fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength. , 2003, Cancer research.

[30]  Dennis W J Klomp,et al.  Optimization of localized 19F magnetic resonance spectroscopy for the detection of fluorinated drugs in the human liver , 2003, Magnetic resonance in medicine.

[31]  L. Abrahmsén,et al.  Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice , 2002, Diabetologia.

[32]  G. Dawson,et al.  Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders. , 2002, The American journal of psychiatry.

[33]  J. Seckl,et al.  Lack of tissue glucocorticoid reactivation in 11β-hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  T. Olsson,et al.  Tissue-specific dysregulation of cortisol metabolism in human obesity. , 2001, The Journal of clinical endocrinology and metabolism.

[35]  H. Jörnvall,et al.  Novel enzymological profiles of human 11beta-hydroxysteroid dehydrogenase type 1. , 2001, Chemico-biological interactions.

[36]  A. Atalla,et al.  Expression and NNK reducing activities of carbonyl reductase and 11beta-hydroxysteroid dehydrogenase type 1 in human lung. , 2001, Chemico-biological interactions.

[37]  P. Renshaw,et al.  Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study. , 2000, The American journal of psychiatry.

[38]  J. Krane,et al.  Detection of dexamethasone in the cornea and lens by NMR spectroscopy , 1999, Graefe's Archive for Clinical and Experimental Ophthalmology.

[39]  W. Oelkers,et al.  Metabolism of Synthetic Corticosteroids by 11β-hydroxysteroid-Dehydrogenases in Man , 1998, Steroids.

[40]  B. Sitter,et al.  Dexamethasone and dexamethasone phosphate detected by 1H and 19F NMR spectroscopy in the aqueous humour. , 1998, Experimental eye research.

[41]  Edwards,et al.  11 b-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress , 1997 .

[42]  B. Walker,et al.  Dexamethasone and 11-dehydrodexamethasone as tools to investigate the isozymes of 11 beta-hydroxysteroid dehydrogenase in vitro and in vivo. , 1997, The Journal of endocrinology.

[43]  P. Stewart,et al.  Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor. , 2008, The Journal of clinical endocrinology and metabolism.

[44]  J. McKew,et al.  beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. , 2007, Bioorganic & medicinal chemistry.

[45]  J. Xiang,et al.  Synthesis and biological evaluation of sulfonamidooxazoles and beta-keto sulfones: selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I. , 2005, Bioorganic & Medicinal Chemistry Letters.

[46]  B. Walker,et al.  Effects of the 11β-Hydroxysteroid Dehydrogenase Inhibitor Carbenoxolone on Insulin Sensitivity in Men with Type 2 Diabetes , 2003 .